Does Medi-Cal Cover Ozempic, Wegovy & Mounjaro for Weight Loss 2026?

Q: What is the difference between Medi-Cal and Medi-Cal Rx?

Medi-Cal is the umbrella California Medicaid program. Medi-Cal Rx is the statewide pharmacy benefit administrator that handles outpatient drug claims for most Medi-Cal members, regardless of which Managed Care plan they are enrolled in. For most GLP-1 PA questions, the relevant formulary is the Medi-Cal Rx Contract Drug List (CDL).

Last updated: May 21, 2026 | Reading time: ~9 minutes | Reviewed by Dr. Marcus Tan, MD

Direct answer — Medi-Cal and GLP-1s in 2026

Partially. Medi-Cal (California Medicaid) covers GLP-1s such as Ozempic, Mounjaro, and Trulicity for type 2 diabetes, generally with prior authorization. Coverage for the weight-loss-only indications (Wegovy, Zepbound, Saxenda) is significantly more restricted in 2026, and most California members seeking GLP-1s for weight loss ultimately access them through cash-pay telehealth rather than Medi-Cal. Specific criteria vary by Medi-Cal Managed Care plan and by Medi-Cal Rx (the pharmacy benefit administered through the state’s contracted pharmacy benefit manager).

Important — verify your specific plan

Insurance formularies change frequently. This guide reflects publicly available coverage details as of May 2026 — confirm coverage for your specific plan by calling Medi-Cal Member Services or your Medi-Cal Managed Care plan member services line, or by checking the Medi-Cal Rx Contract Drug List (CDL) directly at medi-calrx.dhcs.ca.gov. If your prescriber is unsure about the prior authorization or Treatment Authorization Request (TAR) pathway, request a referral to a pharmacy team familiar with Medi-Cal Rx.

Medi-Cal GLP-1 coverage at a glance

Drug	FDA-Approved Indication	Medi-Cal Coverage 2026	Prior Auth / TAR?
Ozempic (semaglutide)	Type 2 diabetes	Covered for T2DM	Often required
Wegovy (semaglutide)	Chronic weight management	Restricted	Yes
Mounjaro (tirzepatide)	Type 2 diabetes	Covered for T2DM	Often required
Zepbound (tirzepatide)	Chronic weight management / OSA	Restricted	Yes
Saxenda (liraglutide)	Chronic weight management	Restricted	Yes
Trulicity (dulaglutide)	Type 2 diabetes	Covered for T2DM	Often required

In plain terms: if you have type 2 diabetes, Medi-Cal generally covers a GLP-1. If you do not, coverage for the weight-loss-only indication is limited, often denied at first PA, and many members ultimately go cash-pay. For a 50-state view, see our Medicaid GLP-1 by State 2026 guide.

Ozempic on Medi-Cal (2026)

Medi-Cal generally covers Ozempic (semaglutide) for type 2 diabetes through Medi-Cal Rx, typically with prior authorization. Common PA elements as of 2026:

– Documented type 2 diabetes diagnosis with ICD-10 coding.
– A1C documentation showing inadequate control on first-line therapy.
– Step-therapy from metformin where clinically appropriate (or documented contraindication / intolerance).
– Prescribing within FDA-labeled indications.

Medi-Cal does not cover Ozempic when prescribed off-label for weight loss in a non-diabetic patient. If your goal is semaglutide for weight management, the on-label medication is Wegovy.

Wegovy on Medi-Cal (2026)

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management. Medi-Cal coverage of Wegovy for the weight-loss indication in 2026 is restricted. State Medicaid programs across the country vary widely on whether they cover obesity-indicated GLP-1s at all, and California’s approach has remained conservative.

When coverage is available, expect:
– Prior authorization or Treatment Authorization Request (TAR).
– BMI threshold (commonly 30 or higher, or 27 with a weight-related comorbidity).
– Documentation of a structured weight-management attempt.
– Ongoing-response criteria at reauthorization.

Many Medi-Cal members who would qualify clinically still face denials on first submission and must appeal. Plan-level managed care formularies (for the medical benefit side) and Medi-Cal Rx (for the pharmacy benefit) can have different expectations. Confirm where your specific drug claim is adjudicated before submitting.

Mounjaro on Medi-Cal (2026)

Mounjaro (tirzepatide) for type 2 diabetes is generally covered through Medi-Cal Rx with prior authorization. PA criteria parallel Ozempic: confirmed T2DM, A1C documentation, step-therapy from metformin where appropriate.

Mounjaro prescribed off-label for weight loss in a non-diabetic member is unlikely to clear PA. If weight loss is the clinical goal and the member is not diabetic, the on-label option is Zepbound — which is more tightly restricted.

Zepbound on Medi-Cal (2026)

Zepbound (tirzepatide) is FDA-approved for chronic weight management and obstructive sleep apnea (OSA) in adults with obesity. Medi-Cal coverage in 2026 mirrors Wegovy: restricted, with PA, BMI, and ongoing-response criteria. The OSA indication may open a separate clinical pathway for members with documented moderate-to-severe sleep apnea — discuss with your prescriber whether that pathway fits your case.

Saxenda on Medi-Cal (2026)

Saxenda (liraglutide) is the older daily-injection GLP-1 for weight management. It is generally restricted on Medi-Cal in 2026 with criteria similar to Wegovy. In practice, Saxenda is prescribed less frequently than semaglutide or tirzepatide because of the daily injection burden and lower average weight loss. It may still be a useful option when newer GLP-1s are unavailable or denied.

Medi-Cal Managed Care plans — formulary varies

Most Medi-Cal enrollees in California are enrolled in a Medi-Cal Managed Care plan (MCP). Pharmacy benefits are administered through Medi-Cal Rx (the statewide pharmacy benefit), but the medical benefit and certain utilization management still flow through the member’s MCP. Common Medi-Cal MCPs in 2026:

– Health Net (Centene) — large statewide footprint.
– Anthem Blue Cross Medi-Cal — multiple counties.
– Molina Healthcare of California — large urban presence.
– Kaiser Permanente Medi-Cal — integrated delivery system; pharmacy coverage flows through Kaiser pharmacies and Medi-Cal Rx coordination.
– L.A. Care Health Plan — Los Angeles County.
– CalOptima — Orange County.
– Inland Empire Health Plan (IEHP) — Riverside / San Bernardino.
– Partnership HealthPlan, CenCal, Central California Alliance for Health — regional plans.

For most GLP-1 questions, the relevant formulary is the Medi-Cal Rx Contract Drug List (CDL) because pharmacy benefits are carved out to Medi-Cal Rx. Confirm with your MCP whether any plan-specific utilization management applies on top of the CDL.

How to file a Medi-Cal Treatment Authorization Request (TAR) for GLP-1

For Medi-Cal Rx pharmacy benefits, the equivalent of a PA is filed through Medi-Cal Rx. Some services and codes still require a TAR through the medical benefit pathway. General workflow in 2026:

1. Office visit and chart documentation. Your prescriber documents BMI, comorbidities, prior weight-loss attempts, and clinical rationale (or for T2DM, your diabetes diagnosis and A1C trajectory).
2. PA / TAR submission. Your prescriber’s office submits to Medi-Cal Rx (typically via the Medi-Cal Rx Customer Service Center, the prescriber portal, or fax). The submission must include diagnosis, medication, dose, and supporting clinical detail.
3. Review and decision. Standard turnaround is typically up to 24 hours for routine pharmacy PAs at Medi-Cal Rx, with expedited review for urgent cases. TARs on the medical side can take longer.
4. Decision. Approval, denial, or request for more information. Decision letters are available to the member.
5. If denied: The member can request a State Fair Hearing and the prescriber can submit additional clinical documentation. Peer-to-peer review may be available depending on the pathway.

A practical note: if your prescriber’s office is not familiar with Medi-Cal Rx GLP-1 PA submissions, the request often gets denied on the first round for missing documentation. A clean, well-documented first submission saves weeks.

GLP-1 alternatives for Medi-Cal members in 2026

If Medi-Cal won’t cover your weight-loss GLP-1, the most common path forward is cash-pay telehealth. Honest framing:

– Compounded semaglutide and tirzepatide are not covered by Medi-Cal. You pay out of pocket.
– Compounded does not equal FDA-approved. The active molecule has well-understood safety data; the specific compounded product has not gone through FDA approval.
– Pricing is well below retail. Cash-pay compounded GLP-1 programs in 2026 commonly run $200–$400 per month. Brand-name Wegovy or Zepbound retail list prices are well above $1,000.
– FDA shortage list status affects compounding legality. The compounding landscape in 2026 has shifted from the 2023–2024 shortage era — confirm with your provider that what they dispense is legally compounded.

Ro Body Program

Established telehealth weight-loss program with branded GLP-1 access (subject to availability) and coaching. Strong clinical workflow. Read our Ro review.

Remedy Meds

Compounded-GLP-1 telehealth with transparent pricing; often the lower entry-price option. Read our Remedy Meds review.

See Remedy Meds pricing

For a head-to-head, see our GLP-1 telehealth comparison.

California-specific notes

California has the largest Medicaid population in the country, so even narrow coverage criteria affect millions of people. A few California-specific dynamics worth knowing:

- CalAIM and obesity care. California's broader Medicaid reform initiative has expanded some chronic-disease care pathways, though pharmacy benefit details for GLP-1s remain governed by Medi-Cal Rx.
- Local clinic density. Federally Qualified Health Centers (FQHCs) across the state often have pharmacists who specialize in Medi-Cal Rx PA workflows — a good first stop if your private practice is unfamiliar with the process.
- County-by-county MCP differences. Coverage administration can feel different in Los Angeles vs. the Bay Area vs. Central Valley, even though the underlying CDL is statewide.

For a deeper view of weight-loss treatment options across the state, see Weight Loss Treatment in California and our California state overview.

Frequently asked questions

Does Medi-Cal cover Ozempic for weight loss?

No. Medi-Cal covers Ozempic for type 2 diabetes through Medi-Cal Rx, typically with prior authorization. It does not cover Ozempic off-label for weight loss in non-diabetic members. For semaglutide on the weight-loss indication specifically, the on-label drug is Wegovy, and Medi-Cal coverage of Wegovy is restricted.

Does Medi-Cal cover Mounjaro for weight loss?

No, not when prescribed for weight loss in non-diabetic members. Medi-Cal generally covers Mounjaro for type 2 diabetes with prior authorization. The weight-loss-indicated version of the same molecule is Zepbound, which faces tighter coverage criteria on Medi-Cal in 2026.

How do I get Wegovy or Zepbound covered by Medi-Cal?

Coverage is restricted and requires prior authorization or a TAR. Typical criteria include BMI thresholds (commonly 30 or higher, or 27 with a weight-related comorbidity), documentation of a structured weight-management attempt, and ongoing-response criteria. Many members face denial on first submission and need to appeal. Confirm specific criteria via Medi-Cal Rx or your MCP.

What is the difference between Medi-Cal and Medi-Cal Rx?

Medi-Cal is the umbrella California Medicaid program. Medi-Cal Rx is the statewide pharmacy benefit administrator that handles outpatient drug claims for most Medi-Cal members, regardless of which Managed Care plan they are enrolled in. For most GLP-1 PA questions, the relevant formulary is the Medi-Cal Rx Contract Drug List (CDL).

Can I use Medi-Cal at a national telehealth provider for GLP-1?

Most national cash-pay telehealth weight-loss programs do not bill Medi-Cal. To use Medi-Cal benefits, you generally need a California-licensed provider contracted with Medi-Cal or your Managed Care plan. Your primary care provider or an FQHC is usually the most practical starting point.

Are there cheaper GLP-1 options for Californians if Medi-Cal won't cover it?

Yes. Cash-pay compounded semaglutide and tirzepatide programs in 2026 commonly run $200–$400 per month, well below brand-name retail. Manufacturer patient-assistance programs (Novo Nordisk for Wegovy/Ozempic/Saxenda, Eli Lilly for Zepbound/Mounjaro) may also reduce out-of-pocket costs for eligible patients.

Does Medi-Cal Cover GLP-1 Weight Loss Drugs in 2026?